BIAL
9.4.2021 14:33:13 CEST | Business Wire | Press release
NOT FOR UK MEDIA DISTRIBUTION
BIAL has developed a new resource centre on its Keep It ON website for World Parkinson’s Day 2021 to empower people living with Parkinson’s disease to stay healthy and active and to help them manage their condition.
Working in partnership with the European Parkinson's Disease Association (EPDA) as well as experts in nutrition, voice and cognition, BIAL plans to create a wealth of resources covering four key areas:
- Nutrition: Nutritionist Diana Miranda explains in her videos the importance of keeping hydrated and gives tips on managing common symptoms in Parkinson’s disease such as constipation. The page also features videos from chef Fábio Bernardino discussing recommended recipes for people with the condition.
- Exercise: Videos of physiotherapist Josefa Domingos from the EPDA demonstrate challenging and engaging exercises for people with Parkinson’s disease to do at home.
- Voice: Voice exercises by Speech Therapist Rita Cardoso are included to help improve communication skills as it is vital people with the condition continue to maintain their social roles and be fully integrated in society.
- Cognition: People with Parkinson’s disease can strengthen their cognitive skills and keep their mind active with helpful mental exercises and games by Isabel Araújo.
Although there is plenty of information available online about eating well and staying active, people with Parkinson’s disease have very specific needs when it comes to nutrition and exercise and the content has been designed with these in mind.
Josefa Domingos and John Dean, EPDA Board members and physiotherapist, comments: “We believe in exercising differently. By combining movement, voice and cognition, you can better replicate and consequently improve daily function and activities in Parkinson’s.”
Rui Sobral, Head of BIAL’s Global Parkinson’s Department, comments: “The new training area we have created supports our ongoing commitment to improve the lives of people with Parkinson’s disease around the world. Working with expert partners is critical to ensuring the resources we create can really make a difference to people with Parkinson’s, helping them to eat well, keep moving and stay active every day.”
More information about the new training area featuring tutorials, videos, tips, recipes and games is available at bial-keepiton.com/training-area/ . The training area will continue to be updated after World Parkinson’s Day with new content.
Since 2017, BIAL has developed global campaigns associated with World Parkinson's Day to increase awareness of the disease and how it affects people directly and indirectly. The films which have been created as part of the campaigns have had more than 1.2 million views to date, and aim to depict how some of the limitations associated with the disease can be overcome with the understanding and support of all. Films include:
- 2020: Keep on moving
- 2019: Speak up for Parkinson's
- 2018: There's no right rhythm for life
- 2017: Me at my best
__________________________________________________________________
About BIAL
Founded in 1924, BIAL's mission is to research, develop and provide therapeutic solutions within the area of health. In the last decades, BIAL has focused strategically on quality, innovation and internationalisation. BIAL is strongly committed to therapeutic innovation, investing more than 20% of its annual turnover into research and development within neurosciences and the cardiovascular system. The company expects to introduce new drugs on the market in the coming years, strengthening its international presence based on proprietary drugs and achieving its goal of supplying innovative products to patients worldwide. For more information on BIAL: www.bial.com
About Parkinson’s Disease
Parkinson's disease is a chronic, progressive neurodegenerative disorder characterised by a strong reduction of the neurotransmitter dopamine, caused by the degeneration of certain neurons in the brain. Epidemiological evidence highlights a complex interaction between genetic vulnerability and environmental factors. The clinical manifestations usually appear after the age of 50 years (the average age of diagnosis is approximately 60 years). The prevalence of the disease is estimated at 300 per 100,000 inhabitants, increasing to 1 in 100 in the age group between 55 and 60 years. The European Parkinson's Disease Association (EPDA) estimates that approx. 1.2 million people suffer from this disease in Europe. The diagnosis of Parkinson's disease is based on clinical observation and relies on three key elements: bradykinesia (slow movements), resting tremor, and rigidity (muscle stiffness). Of these, bradykinesia must be present, with at least either tremor or rigidity. Other common symptoms are postural instability, reduced facial expression and blinking, and a slouching posture. The disease progressively incapacitates patients, causing hindrance in their lives and daily activities.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210409005241/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics Receives EU/EEA Approval for XEOMIN® for the Treatment of Pediatric Spasticity Associated With Pes Equinus17.9.2026 08:00:00 CEST | Press release
Approval expands XEOMIN use to include the symptomatic treatment of spasticity associated with pes equinus in children and adolescents with cerebral palsy aged 2 to 17 years. Approval includes both children and adolescents who are able to walk and those who are non-ambulant, broadening the population eligible for XEOMIN treatment Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced that it has received approval in the European Union (EU) / European Economic Area (EEA) for XEOMIN® (incobotulinumtoxinA) for the symptomatic treatment of spasticity associated with pes equinus, a condition in which tight calf muscles cause the foot to point downward, in ambulant and non-ambulant children and adolescents with cerebral palsy (CP) aged 2 to 17 years.1,2 This approval expands access to an established botulinum neurotoxin therapy for some of the youngest and most vulnerable patients across Europe. Spasticity is a common and often disruptive symptom in childr
Mediterranean Network for Haemoglobinopathies Launches in Rome, Connecting Clinical Experts and Patient Leaders to Advance Equitable Care17.9.2026 08:00:00 CEST | Press release
Founding members endorse a Declaration of Intent centred on practical collaboration, meaningful patient participation and evidence-based improvement. The Network will address shared challenges including blood supply, unequal access to specialist care and innovation, real-world evidence and European policy change. Avanzanite Bioscience becomes Founding Sponsor to support an independent platform designed to connect expertise, highlight unmet needs and help turn scientific and patient knowledge into practical collaboration. The Mediterranean Network for Haemoglobinopathies (MNfH) was recently launched at Palazzo Wedekind in Rome, bringing together leading clinicians and patient representatives from Cyprus, Greece, and Italy, with the Thalassaemia International Federation (TIF). Supported by Avanzanite Bioscience as Founding Sponsor, the independent regional platform will connect expertise across borders, strengthen the patient voice, and turn shared knowledge into practical initiatives th
IKI Advances Promotional Forecast Accuracy by More Than 10 Points With SymphonyAI17.9.2026 07:03:00 CEST | Press release
Lithuania's second-largest grocer brings AI-driven promotional planning to its network of 250 stores, with early results already showing double-digit gains in forecast accuracy SymphonyAI, a global leader in Vertical AI, today announced that IKI, one of Lithuania's largest grocery retailers, is implementing SymphonyAI's Promotional Evaluation and Promotional Planning solutions across its network of 250 stores, as part of its strategy to strengthen data-driven promotional planning. IKI continuously evaluates opportunities to strengthen its category management and promotional planning capabilities. As promotional programs become increasingly sophisticated, the retailer has invested in advanced analytics and AI-driven forecasting to support data-driven decision making across its business. In its initial work with SymphonyAI across select categories, IKI has seen promotional forecast accuracy improve by more than 10 percentage points, along with a reduction in stock-outs during promotional
Lattice Advances FPGA Design with New Leadership AI-Driven Development Tool, Lattice Prompt17.9.2026 04:00:00 CEST | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable and platform firmware leader, today introduced a new leadership AI-powered FPGA development tool for small and mid-range FPGAs that redefines how FPGA developers work across the full design flow. Lattice Prompt pairs with AI agentic tools developers already use, combining them with Lattice design tools, knowledge base, and documentation to turn natural language inputs into validated responses, dramatically accelerating FPGA development while optimizing design performance and capability. "Accelerating time-to-market demands and rising design complexity are putting mounting pressure on FPGA developers to do more with every design cycle," said Esam Elashmawi, Chief Strategy and Marketing Officer, Lattice Semiconductor. "Lattice Prompt gives developers AI-assisted access to the full design flow, grounded in Lattice's validated knowledge, so they can focus on what matters most: building differentiated systems." Lattice Prompt:
Lattice Expands Secure Control FPGA Leadership with New Lattice Mach-N2 Family17.9.2026 04:00:00 CEST | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable and platform firmware leader, today announced Lattice Mach™-N2 FPGA family, extending its long-running secure control FPGA leadership with new devices purpose-built for system control and security in modern infrastructure. Built on the Lattice Nexus™ 2 small FPGA platform, Mach-N2 combines integrated flash, a hardware Root of Trust, and CNSA 2.0-compliant post-quantum cryptography (PQC) with crypto agility for trusted, always-on system control and security across next-generation systems. "The demands on system control and security are accelerating as post-quantum mandates take hold, and customers building long-lifecycle infrastructure seek solutions that will help them design with today and tomorrow’s security needs in mind," said Esam Elashmawi, Chief Strategy and Marketing Officer, Lattice Semiconductor. "Mach-N2 represents a significant step forward in logic density and bandwidth while adding the most complete post-qua
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom